NCT07791277

Brief Summary

Study Summary: Comparison of Two Treatments for Female Myofascial Pelvic Pain Syndrome The goal of this study is to compare two treatment methods-precise AI-controlled radiofrequency therapy versus biofeedback combined with electrical stimulation-for their clinical effectiveness in female Myofascial Pelvic Pain Syndrome . The study also evaluates the differences between the two therapies in relieving pain, improving sexual function, restoring pelvic floor muscle strength, and reducing anxiety. The main questions it aims to answer are: Does precise AI-controlled radiofrequency therapy outperform biofeedback combined with electrical stimulation in relieving pain and reducing pelvic floor hypertonicity? Do the two therapies differ in their effects on improving patients' sexual function and anxiety levels? Which treatment regimen is more effective in restoring pelvic floor muscle strength and stability? Researchers randomly assigned 70 female MPPS patients into two groups (35 patients each). One group received precise AI-controlled radiofrequency therapy (5 sessions, completed over approximately 12 weeks), while the other group received biofeedback combined with electrical stimulation (10 sessions, completed over approximately 3 weeks). Treatment outcomes were compared using Glazer pelvic floor surface electromyography (sEMG) assessment, Visual Analogue Scale (VAS) pain scores, the Female Sexual Function Index (FSFI), and anxiety scores. Participants will: Receive pelvic floor physical therapy for 3 to 12 weeks, depending on their group assignment Undergo Glazer pelvic floor surface electromyography (sEMG) assessment before and after treatment to measure resting tension and muscle strength of the pelvic floor muscles Complete pain (VAS), sexual function (FSFI), and anxiety (HADS-A) questionnaires before and after treatment Be guided throughout the treatment by professional pelvic floor rehabilitation therapists, who will adjust parameters (e.g., current intensity, radiofrequency temperature) based on the patient's subjective comfort level during treatment

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 14, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 10, 2026

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

August 16, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 16, 2026

Completed
11 days until next milestone

First Posted

Study publicly available on registry

August 27, 2026

Completed
Last Updated

August 27, 2026

Status Verified

August 1, 2026

Enrollment Period

3 months

First QC Date

August 16, 2026

Last Update Submit

August 25, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • visual analog scale (VAS)

    Visual Analogue Scale (VAS): The scale ranges from 0 to 10.1-3 points: mild pain, tolerable, barely interfering with daily activities and sleep;4-6 points: moderate pain, obvious discomfort, may disturb sleep, analgesic intervention may be needed;7-10 points: severe pain, unbearable, significantly impairs sleep and daily activities.

    "Prior to treatment initiation or on Day 1 of treatment" "After the end of treatment or at a mean of 4 to 12 weeks"

Study Arms (2)

Precision AI temperature-controlled radiofrequency group

EXPERIMENTAL
Device: Intervention 1:Precision AI Temperature-Controlled Radiofrequency

Biofeedback combined with electrical stimulation group

ACTIVE COMPARATOR

Biofeedback combined with electrical stimulation group

Device: Intervention 2:Biofeedback Combined with Electrical Stimulation

Interventions

Precision AI temperature-controlled radiofrequency therapy is delivered using the MLD UR80 device with an intravaginal probe. The device applies controlled thermal energy (40-45°C, max 48°C) to deep pelvic floor tissues, promoting collagen remodeling, enhancing microcirculation, and relieving myofascial trigger points. An AI system monitors impedance and temperature in real time, automatically adjusting energy output and activating safety alerts at 45°C with mandatory shutdown at 48°C. Each 30-minute session includes audio-guided pelvic floor exercises. The complete protocol comprises five sessions over approximately 12 weeks (first three sessions at 14-day intervals; remaining two at 21-day intervals).

Also known as: Precision AI Temperature-Controlled Radiofrequency
Precision AI temperature-controlled radiofrequency group

Biofeedback combined with electrical stimulation is delivered using the MLD B2 biofeedback stimulator (Nanjing Medlander Medical Co., Ltd.) with an intravaginal electrode and surface electrodes placed on the abdomen and knees. The device provides combined electrical stimulation (0-60 mA) with real-time biofeedback signals displayed on a screen, enabling patients to visualize pelvic floor muscle activity and perform guided Kegel and breathing relaxation exercises. Each 30-minute session integrates three intelligent stimulation protocols selected by the device based on prior treatment records. The complete course consists of 10 sessions performed every other day, totaling approximately 3 weeks. Patients may discontinue at any time upon request.

Also known as: Active Comparator
Biofeedback combined with electrical stimulation group

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Female patients with a confirmed diagnosis of MPPS
  • Have signed the informed consent form
  • Aged over 18 years old and sexually active

You may not qualify if:

  • Concurrent vaginitis;
  • Pregnancy, pre-pregnancy, or within 6 months postpartum
  • Abnormal vaginal bleeding
  • Severe systemic conditions
  • Internal metallic implants
  • Skin lesions in the treatment region
  • Organic pelvic pathologies
  • Systemic or neuropathic pain syndromes
  • Concurrent use of pharmacological therapy
  • intolerance to the current treatment protocol.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jiangxi Maternal and Child Health Hospital

Nanchang, Jiangxi, 330000, China

Location

MeSH Terms

Conditions

Fibromyalgia

Interventions

Electric Stimulation

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Physical StimulationInvestigative Techniques

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 16, 2026

First Posted

August 27, 2026

Study Start

May 14, 2026

Primary Completion

August 10, 2026

Study Completion

August 16, 2026

Last Updated

August 27, 2026

Record last verified: 2026-08

Locations